They are considered to have less risk than some of the most performed surgeries in the United States, such as gallbladder surgery and even knee replacement
When researchers tested it at higher doses, the results were jaw-dropping
Introduction Thyroid diseases are common in some metabolic disorders, such as diabetes mellitus (DM) and obesity
Glucagon receptor activation increases metabolic rate by stimulating thermogenesis in brown adipose tissue and enhancing mitochondrial activity in hepatocytes and skeletal muscle
weeks 1-16 on tirzepatide Semaglutide GI rate / 44.2% nausea, 31.5% diarrhea, 23.4% constipation in STEP-1 (N=1,961) Tirzepatide GI rate / approximately 80% of patients on 15 mg reported at least one GI effect in SURMOUNT-1 (N=2,539) First-line fix / avoid high-sulfur foods (eggs, garlic, cruciferous vegetables) on injection days Medication option / simethicone (Gas-X, 125 mg) or bismuth subsalicylate (Pepto-Bismol) may reduce odor and frequency Serious warning / new right-upper-quadrant pain plus burping may signal gallbladder disease, not routine GI upset Discontinuation / roughly 7% of semaglutide 2.4 mg patients stopped due to GI side effects in STEP-1 Dose strategy / slower titration reduces GI burden without meaningfully reducing weight loss outcomes What Causes Sulfur Burps on GLP-1 Drugs GLP-1 receptor agonists slow gastric emptying as a deliberate pharmacological effect
Clinical evidence indicates substantial decreases in hepatic fat accumulation before the onset of severe illness, with studies documenting alanine transaminase (ALT) normalisation in 40% of individuals exhibiting baseline increases (Buse et al
